Pfizer withdraws sickle cell disease treatment on risk of complication, death
Pfizer ends all studies and access to Oxbryta as risks outweigh benefits, based on clinical data
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Oxbryta
Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare haematology
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with…